Key result
An extended dosing interval of 28 days or more between the first two doses of BNT162b2 reduced the risk of Covid-19 infection by 29.2% (aOR 0.718) compared to a regular interval in children and adolescents.
Why the study?
Does an extended dosing interval of the BNT162b2 vaccine reduce the risk of Covid-19 infection in children and adolescents aged 5-17 years?
Case-Control (n=26,973)
Does an extended dosing interval of the BNT162b2 vaccine reduce the risk of Covid-19 infection in children and adolescents aged 5-17 years?
Odds Ratio: 0.718 (95% CI 0.619–0.833)
Extending the dosing interval of the BNT162b2 vaccine to ≥28 days or ≥8 weeks in children and adolescents significantly reduces the risk of Covid-19 infection compared to the standard 21-27 day interval.
Extended intervals linked to 29% lower infection risk in youth; supports extended dosing to reduce myocarditis without losing effectiveness.
Extended intervals between the first and second doses of mRNA Covid-19 vaccines may reduce the risk of myocarditis in children and adolescents. However, vaccine effectiveness after this extension remains unclear. To examine this potential variable effectiveness, we conducted a population-based nested case-control study of children and adolescents aged 5-17 years who had received two doses of BNT162b2 in Hong Kong. From January 1 to August 15, 2022, 5396 Covid-19 cases and 202 Covid-19 related hospitalizations were identified and matched with 21,577 and 808 controls, respectively. For vaccine recipients with extended intervals [≥28 days, adjusted odds ratio 0.718, 95% Confidence Interval: 0.619, 0.833] there was a 29.2%-reduced risk of Covid-19 infection compared to those with regular intervals (21-27 days). If the threshold was set at eight weeks, the risk reduction was estimated at 43.5% (aOR 0.565, 95% CI: 0.456, 0.700). In conclusion, longer dosing intervals for children and adolescents should be considered.
No takes yet. Share an insight, caveat, or question.
Lai et al. (2023) conducted a case-control in Covid-19 infection (n=26,973). Extended dosing interval (≥28 days) of BNT162b2 vs. Regular dosing interval (21-27 days) was evaluated on Covid-19 infection (first recorded SARS-CoV-2 positive PCR) (aOR 0.718, 95% CI 0.619, 0.833). An extended dosing interval of 28 days or more between the first two doses of BNT162b2 reduced the risk of Covid-19 infection by 29.2% (aOR 0.718) compared to a regular interval in children and adolescents.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: